SENS-401 not checked

Sensorion

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“43.5 mg dose groupe: tablets of 14.5 mg, oral route, by mouth, twice a day, during 4 weeks”In the company’s words, NCT03603314 on ClinicalTrials.gov
Tested for
Severe Sudden Sensorineural Hearing Loss, Hearing Loss, Hearing Loss Ototoxic
Main trialPhase 2/3
“Primary objective of the study is to assess the efficacy of SENS-401 on hearing loss in comparison to placebo at the end of the 4-week treatment period”In the company’s words, NCT03603314 on ClinicalTrials.gov

Other drugs for Hearing Loss

All 21 drugs for Hearing Loss

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 2/3Completed 4 Nov 2021 Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Phase 2Completed 18 Dec 2023 Evaluation of the Presence of SENS-401 in the Perilymph
Phase 2Completed 16 Apr 2025 SENS-401 to Prevent the Ototoxicity Induced by Cisplatin in Adult Subjects With a Neoplastic Disease
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow SENS-401

Following is part of Solo: you see every change to SENS-401 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in